NewAmsterdam Pharma [NAMSW] vs Orchestra BioMed [OBIO] Detailed Stock Comparison

NewAmsterdam Pharma Company N.V.

NASDAQ
Loading...

Orchestra BioMed Holdings, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: NewAmsterdam Pharma Company N.V. wins in 8 metrics, Orchestra BioMed Holdings, Inc. wins in 5 metrics, with 1 ties. NewAmsterdam Pharma Company N.V. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric NewAmsterdam Pharma Company N.V. Orchestra BioMed Holdings, Inc. Better
Price-to-Book Ratio 3.72 4.48 NewAmsterdam Pharma Company N.V.
Debt-to-Equity Ratio 0.03 25.17 NewAmsterdam Pharma Company N.V.
PEG Ratio N/A -2.47 N/A
EV/EBITDA 2.23 -3.22 NewAmsterdam Pharma Company N.V.
Profit Margin (TTM) 0.00% -157.40% NewAmsterdam Pharma Company N.V.
Operating Margin (TTM) -206,187.50% 21.85% Orchestra BioMed Holdings, Inc.
EBITDA Margin (TTM) N/A 21.85% N/A
Return on Equity -28.29% -109.41% NewAmsterdam Pharma Company N.V.
Return on Assets (TTM) -17.27% -33.90% NewAmsterdam Pharma Company N.V.
Free Cash Flow (TTM) $-148.03M $-49.45M Orchestra BioMed Holdings, Inc.
1-Year Return 99.79% 32.69% NewAmsterdam Pharma Company N.V.
Price-to-Sales Ratio (TTM) 0.00 7.36 Tie
Enterprise Value $-489.80M $165.62M Orchestra BioMed Holdings, Inc.
EV/Revenue Ratio -21.77 4.95 Orchestra BioMed Holdings, Inc.
Gross Profit Margin (TTM) N/A 99.84% N/A
Revenue per Share (TTM) $0 $1 Orchestra BioMed Holdings, Inc.
Earnings per Share (Diluted) N/A $-1.11 N/A
Beta (Stock Volatility) 0.13 0.60 NewAmsterdam Pharma Company N.V.
Short % of Float N/A 2.46% N/A

NewAmsterdam Pharma Company N.V. vs Orchestra BioMed Holdings, Inc. Stock Performance Analysis

Loading Price Chart...

NAMSW
OBIO

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
NewAmsterdam Pharma Company N.V.0.00%-3.98%-31.16%1.62%-24.50%-18.61%
Orchestra BioMed Holdings, Inc.-3.17%0.51%6.72%-12.75%-7.67%-7.89%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
NewAmsterdam Pharma Company N.V.99.79%830.69%1,593.69%706.87%706.87%706.87%
Orchestra BioMed Holdings, Inc.32.69%-55.09%-60.58%-49.38%-49.38%-49.38%

Performance & Financial Health Analysis: NewAmsterdam Pharma Company N.V. vs Orchestra BioMed Holdings, Inc.

MetricNAMSWOBIO
Market Information
Market Cap i$0$242.86M
Market Cap CategoryMicro capMicro cap
10 Day Avg. Volume i520133,035
90 Day Avg. Volume i1,653183,128
Last Close$18.80$3.97
52 Week Range$7.80 - $30.45$2.20 - $5.42
% from 52W High-38.26%-26.81%
All-Time High$30.00 (May 11, 2026)$23.39 (Apr 03, 2023)
% from All-Time High-37.33%-83.03%
Growth Metrics
Quarterly Revenue Growth-1.00%121.20%
Quarterly Earnings Growth-1.00%121.20%
Financial Health
Profit Margin (TTM) i0.00%-1.57%
Operating Margin (TTM) i-2,061.88%0.22%
Return on Equity (TTM) i-0.28%-1.09%
Debt to Equity (MRQ) i0.0325.17
Cash & Liquidity
Book Value per Share (MRQ)$5.97$0.94
Cash per Share (MRQ)$5.53$1.82
Operating Cash Flow (TTM) i$-147,783,008$-48,963,000
Levered Free Cash Flow (TTM) i$-112,909,872$-20,247,876
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: NewAmsterdam Pharma Company N.V. vs Orchestra BioMed Holdings, Inc.

MetricNAMSW (Apr 24, 2026)OBIO (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) iN/AN/A
Forward P/E iN/A-2.47
PEG Ratio iN/A-2.47
Price to Sales (TTM) i0.007.36
Price to Book (MRQ) i3.724.48
Market Capitalization
Market Capitalization i$0$242.86M
Enterprise Value i$-489,800,000$165.62M
Enterprise Value Metrics
Enterprise to Revenue i-21.774.95
Enterprise to EBITDA i2.23-3.22
Risk & Other Metrics
Beta i0.130.60
Book Value per Share (MRQ) i$5.97$0.94

Financial Statements Comparison: NewAmsterdam Pharma Company N.V. vs Orchestra BioMed Holdings, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNAMSW (2025)OBIO (2025)
Revenue/Sales i22.50M33.48M
Cost of Goods Sold iN/A190,000
COGS % of Revenue i0.0%0.6%
Gross Profit iN/A33.29M
Gross Margin i0.0%99.4%
Research & Development i141.83M58.19M
Operating Income (EBIT) i-225.68M-51.81M
Operating Margin i-1,002.9%-154.7%
EBITDA i-219.74M-51.48M
EBITDA Margin i-976.5%-153.8%
Pre-Tax Income i-203.82M-52.70M
Pre-Tax Income % of Revenue i-905.7%-157.4%
Income Tax i0N/A
Income Tax % of Revenue i0.0%0.0%
Net Income (Profit) i-203.82M-52.70M
Profit Margin i-905.7%-157.4%

Balance Sheet & Liquidity Metrics

MetricNAMSW (2025)OBIO (2025)
Cash & Equivalents i490.00M34.69M
Total Current Assets i675.70M107.91M
Total Current Assets % of Revenue i3,002.7%322.3%
Total Current Liabilities i85.79M16.74M
Total Current Liabilities % of Revenue i381.2%50.0%
Long-Term Debt i66,00015.20M
Long-Term Debt % of Revenue i0.3%45.4%
Total Shareholders Equity i683.43M53.57M
Retained Earnings i-762.39M-362.58M
Retained Earnings % of Revenue i-3,387.9%-1,082.9%
Property, Plant & Equipment i568,0004.24M

Cash Flow Statement Comparison

MetricNAMSW (2025)OBIO (2025)
Operating Cash Flow i-141.29M-54.46M
Operating Cash Flow % of Revenue i-627.9%-162.6%
Capital Expenditures i-246,000-489,000
Free Cash Flow i-148.03M-49.45M
FCF Margin i-657.8%-147.7%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricNAMSWOBIO
Shares Short iN/A957,939
Short Ratio iN/A3.91
Short % of Float iN/A2.46%
Shares Outstanding i114.40M57.03M
Float Shares i71.47M32.49M
% Held by Insiders iN/A27.92%
% Held by Institutions iN/A38.23%
% Held by Public iN/A33.85%

Dividend Analysis & Yield Comparison: NewAmsterdam Pharma Company N.V. vs Orchestra BioMed Holdings, Inc.

MetricNAMSWOBIO
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A